Molecular pathways: Interleukin-35 in autoimmunity and cancer

Clinical Cancer Research

Volumn 22, Issue 20, 2016, Pages 4973-4978

  Pylayeva Gupta, Yuliya ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; INTERLEUKIN 12; INTERLEUKIN 35; JANUS KINASE; STAT PROTEIN; STAT1 PROTEIN; STAT3 PROTEIN; STAT4 PROTEIN; TRANSCRIPTION FACTOR FOXP3; IL36A PROTEIN, HUMAN; INTERLEUKIN 1; TUMOR MARKER;

ARTICLE; AUTOIMMUNITY; B LYMPHOCYTE; CANCER GROWTH; CANCER THERAPY; CARCINOGENESIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL POPULATION; CELL PROLIFERATION; CELLS BY BODY ANATOMY; COLORECTAL CANCER; EFFECTOR CELL; HOMEOSTASIS; HUMAN; IMMUNE RESPONSE; INFLAMMATORY DISEASE; LEUKEMIA; LUNG CANCER; LYMPHOMA; MELANOMA; MOUSE; NEOPLASM; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TARGET CELL; TUMOR CELL; ANIMAL; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; METABOLISM; SIGNAL TRANSDUCTION;

ANIMALS; AUTOIMMUNITY; B-LYMPHOCYTES; BIOMARKERS, TUMOR; HUMANS; IMMUNE TOLERANCE; INTERLEUKIN-1; MICE; NEOPLASMS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, REGULATORY;

EID: 84991769636     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-16-0743     Document Type: Article

References (55)

1. Vignali DA, Kuchroo VK. IL-12 family cytokines: immunological playmakers. Nat Immunol 2012;13:722-8.
2. Devergne O, Birkenbach M, Kieff E. Epstein-Barr virus-induced gene 3 and the p35 subunit of interleukin 12 form a novel heterodimeric hematopoietin. Proc Natl Acad Sci U S A 1997;94:12041-6.
3. Collison LW, Workman CJ, Kuo TT, Boyd K, Wang Y, Vignali KM, et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 2007;450:566-9.
4. Chaturvedi V, Collison LW, Guy CS, Workman CJ, Vignali DA. Cutting edge: Human regulatory T cells require IL-35 to mediate suppression and infectious tolerance. J Immunol 2011;186:6661-6.
5. Dixon KO, van der Kooij SW, Vignali DA, van Kooten C. Human tolerogenic dendritic cells produce IL-35 in the absence of other IL-12 family members. Eur J Immunol 2015;45:1736-47.
6. Shen P, Roch T, Lampropoulou V, O'Connor RA, Stervbo U, Hilgenberg E, et al. IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases. Nature 2014;507: 366-70.
7. Wang RX, Yu CR, Dambuza IM, Mahdi RM, Dolinska MB, Sergeev YV, et al. Interleukin-35 induces regulatory B cells that suppress autoimmune disease. Nat Med 2014;20:633-41.
8. Pylayeva-Gupta Y, Das S, Handler JS, Hajdu CH, Coffre M, Koralov SB, et al. IL35-producing B cells promote the development of pancreatic neoplasia. Cancer Discov 2016;6:247-55.
9. Nicholl MB, Ledgewood CL, Chen X, Bai Q, Qin C, Cook KM, et al. IL-35 promotes pancreas cancer growth through enhancement of proliferation and inhibition of apoptosis: evidence for a role as an autocrine growth factor. Cytokine 2014;70:126-33.
10. Wang Z, Liu JQ, Liu Z, Shen R, Zhang G, Xu J, et al. Tumor-derived IL-35 promotes tumor growth by enhancing myeloid cell accumulation and angiogenesis. J Immunol 2013;190:2415-23.
11. Long J, Zhang X, Wen M, Kong Q, Lv Z, An Y, et al. IL-35 overexpression increases apoptosis sensitivity and suppresses cell growth in human cancer cells. Biochem Biophys Res Commun 2013;430: 364-9.
12. Li X, Mai J, Virtue A, Yin Y, Gong R, Sha X, et al. IL-35 is a novel responsive anti-inflammatory cytokine-a new system of categorizing anti-inflammatory cytokines. PLoS One 2012;7:e33628.
13. Mattner F, Magram J, Ferrante J, Launois P, Di Padova K, Behin R, et al. Genetically resistant mice lacking interleukin-12 are susceptible to infection with Leishmania major and mount a polarized Th2 cell response. Eur J Immunol 1996;26:1553-9.
14. Nieuwenhuis EE, Neurath MF, Corazza N, Iijima H, Trgovcich J, Wirtz S, et al. Disruption of T helper 2-immune responses in Epstein-Barr virusinduced gene 3-deficient mice. Proc Natl Acad Sci U S A 2002;99: 16951-6.
15. Collison LW, Chaturvedi V, Henderson AL, Giacomin PR, Guy C, Bankoti J, et al. IL-35-mediated induction of a potent regulatory T cell population. Nat Immunol 2010;11:1093-101.
16. Olson BM, Sullivan JA, Burlingham WJ. Interleukin 35: a key mediator of suppression and the propagation of infectious tolerance. Front Immunol 2013;4:315.
17. Collison LW, Delgoffe GM, Guy CS, Vignali KM, Chaturvedi V, Fairweather D, et al. The composition and signaling of the IL-35 receptor are unconventional. Nat Immunol 2012;13:290-9.
18. Garbers C, Hermanns HM, Schaper F, Muller-Newen G, Grotzinger J, Rose-John S, et al. Plasticity and cross-talk of interleukin 6-type cytokines. Cytokine Growth Factor Rev 2012;23:85-97.
19. Presky DH, Yang H, Minetti LJ, Chua AO, Nabavi N, Wu CY, et al. A functional interleukin 12 receptor complex is composed of two betatype cytokine receptor subunits. Proc Natl Acad Sci U S A 1996;93: 14002-7.
20. Grohmann U, Belladonna ML, Bianchi R, Orabona C, Ayroldi E, Fioretti MC, et al. IL-12 acts directly on DC to promote nuclear localization of NF-kappaB and primes DC for IL-12 production. Immunity 1998;9: 315-23.
21. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003;3:133-46.
22. Saito M, Yoshida K, Hibi M, Taga T, Kishimoto T. Molecular cloning of a murine IL-6 receptor-associated signal transducer, gp130, and its regulated expression in vivo. J Immunol 1992;148:4066-71.
23. Lesina M, Kurkowski MU, Ludes K, Rose-John S, Treiber M, Kloppel G, et al. Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Cancer Cell 2011;19:456-69.
24. Collison LW, Pillai MR, Chaturvedi V, Vignali DA. Regulatory T cell suppression is potentiated by target T cells in a cell contact, IL-35- and IL-10-dependent manner. J Immunol 2009;182:6121-8.
25. Pillai MR, Collison LW, Wang X, Finkelstein D, Rehg JE, Boyd K, et al. The plasticity of regulatory T cell function. J Immunol 2011;187: 4987-97.
26. Bettini M, Castellaw AH, Lennon GP, Burton AR, Vignali DA. Prevention of autoimmune diabetes by ectopic pancreatic beta-cell expression of interleukin-35. Diabetes 2012;61:1519-26.
27. Wirtz S, Billmeier U, McHedlidze T, Blumberg RS, Neurath MF. Interleukin-35 mediates mucosal immune responses that protect against T-cell-dependent colitis. Gastroenterology 2011;141:1875-86.
28. Egwuagu CE, Yu CR, Sun L, Wang R. Interleukin 35: critical regulator of immunity and lymphocyte-mediated diseases. Cytokine Growth Factor Rev 2015;26:587-93.
29. Niedbala W, Wei XQ, Cai B, Hueber AJ, Leung BP, McInnes IB, et al. IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells. Eur J Immunol 2007;37: 3021-9.
30. Kochetkova I, Golden S, Holderness K, Callis G, Pascual DW. IL-35 stimulation of CD39+ regulatory T cells confers protection against collagen II-induced arthritis via the production of IL-10. J Immunol 2010;184: 7144-53.
31. Olson BM, Jankowska-Gan E, Becker JT, Vignali DA, Burlingham WJ, McNeel DG. Human prostate tumor antigen-specific CD8+ regulatory T cells are inhibited by CTLA-4 or IL-35 blockade. J Immunol 2012;189: 5590-601.
32. Yang J, Yang M, Htut TM, Ouyang X, Hanidu A, Li X, et al. Epstein-Barr virus-induced gene 3 negatively regulates IL-17, IL-22 and RORgamma t. Eur J Immunol 2008;38:1204-14.
33. Liu JQ, Liu Z, Zhang X, Shi Y, Talebian F, Carl JW Jr, et al. Increased Th17 and regulatory T cell responses in EBV-induced gene 3-deficient mice lead to marginally enhanced development of autoimmune encephalomyelitis. J Immunol 2012;188:3099-106.
34. Fillatreau S, Sweenie CH, McGeachy MJ, Gray D, Anderton SM. B cells regulate autoimmunity by provision of IL-10. Nat Immunol 2002;3: 944-50.
35. Mauri C, Ehrenstein MR. The 'short' history of regulatory B cells. Trends Immunol 2008;29:34-40.
36. Yanaba K, Bouaziz JD, Haas KM, Poe JC, Fujimoto M, Tedder TF. A regulatory B cell subset with a unique CD1dhiCD5+ phenotype controls T cell-dependent inflammatory responses. Immunity 2008;28: 639-50.
37. Barr TA, Shen P, Brown S, Lampropoulou V, Roch T, Lawrie S, et al. B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells. J Exp Med 2012;209: 1001-10.
38. Mauri C, Bosma A. Immune regulatory function of B cells. Annu Rev Immunol 2012;30:221-41.
39. Banchereau J, Pascual V, O'Garra A. From IL-2 to IL-37: the expanding spectrum of anti-inflammatory cytokines. Nat Immunol 2012;13: 925-31.
40. Kalampokis I, Yoshizaki A, Tedder TF. IL-10-producing regulatory B cells (B10 cells) in autoimmune disease. Arthritis Res Ther 2013; 15Suppl 1:S1.
41. Wilson MS, Taylor MD, O'Gorman MT, Balic A, Barr TA, Filbey K, et al. Helminth-induced CD19+CD23hi B cells modulate experimental allergic and autoimmune inflammation. Eur J Immunol 2010;40: 1682-96.
42. Su Y, Zhang AH, Noben-Trauth N, Scott DW. B-cell gene therapy for tolerance induction: host but not donor B-cell derived IL-10 is necessary for tolerance. Front Microbiol 2011;2:154.
43. Flores-Borja F, Bosma A, Ng D, Reddy V, Ehrenstein MR, Isenberg DA, et al. CD19+CD24hiCD38hi B cells maintain regulatory T cells while limiting TH1 and TH17 differentiation. Sci Transl Med 2013;5: 173ra23.
44. Sawant DV, Hamilton K, Vignali DA. Interleukin-35: expanding its job profile. J Interferon Cytokine Res 2015;35:499-512.
45. Tirotta E, Duncker P, Oak J, Klaus S, Tsukamoto MR, Gov L, et al. Epstein-Barr virus-induced gene 3 negatively regulates neuroinflammation and T cell activation following coronavirus-induced encephalomyelitis. J Neuroimmunol 2013;254:110-6.
46. Huang CH, Loo EX, Kuo IC, Soh GH, Goh DL, Lee BW, et al. Airway inflammation and IgE production induced by dust mite allergen-specific memory/effector Th2 cell line can be effectively attenuated by IL-35. J Immunol 2011;187:462-71.
47. Hu Y, Dong C, Yue Y, Xiong S. In vivo delivery of interleukin-35 relieves coxsackievirus-B3-induced viral myocarditis by inhibiting Th17 cells. Arch Virol 2014;159:2411-9.
48. Liu Y, Wu Y, Wang Y, Cai Y, Hu B, Bao G, et al. IL-35mitigates murine acute graft-versus-host disease with retention of graft-versus-leukemia effects. Leukemia 2015;29:939-46.
49. Huang Y, Lin YZ, Shi Y, Ji QW. IL-35: a potential target for the treatment of atherosclerosis. Pharmazie 2013;68:793-5.
50. Turnis ME, Sawant DV, Szymczak-Workman AL, Andrews LP, Delgoffe GM, Yano H, et al. Interleukin-35 limits anti-tumor immunity. Immunity 2016;44:316-29.
51. Niedobitek G, Pazolt D, Teichmann M, Devergne O. Frequent expression of the Epstein-Barr virus (EBV)-induced gene, EBI3, an IL-12 p40-related cytokine, in Hodgkin and Reed-Sternberg cells. J Pathol 2002; 198:310-6.
52. Wang J, Tao Q, Wang H, Wang Z, Wu F, Pan Y, et al. Elevated IL-35 in bone marrow of the patients with acute myeloid leukemia. Hum Immunol 2015;76:681-6.
53. Zeng JC, Zhang Z, Li TY, Liang YF, Wang HM, Bao JJ, et al. Assessing the role of IL-35 in colorectal cancer progression and prognosis. Int J Clin Exp Pathol 2013;6:1806-16.
54. Jin P, Ren H, Sun W, Xin W, Zhang H, Hao J. Circulating IL-35 in pancreatic ductal adenocarcinoma patients. Hum Immunol 2014;75: 29-33.
55. Sauer KA, Maxeiner JH, Karwot R, Scholtes P, Lehr HA, Birkenbach M, et al. Immunosurveillance of lung melanoma metastasis in EBI-3-deficient mice mediated by CD8+ T cells. J Immunol 2008;181: 6148-57.